Endometrial Neoplasm Malignant Stage IPhase 2/3NCT03241914
Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer
A Phase 2/3 study testing Megestrol Acetate and Levonorgestrel-releasing Intrauterine System(LNG-IUS) in people with Endometrial Neoplasm Malignant Stage I, run by Fudan University at 1 site in China.
Trial summary
To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate alone in patients with early endometrial cancer. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Endometrial Neoplasm Malignant Stage I
- What is being tested?
- Megestrol Acetate and Levonorgestrel-releasing Intrauterine System(LNG-IUS)
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteChina
- Study dates
- 4 Jul 2017to 18 Jun 2020
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Primarily have a confirmed diagnosis of endometrioid endometrial cancer based upon hysteroscopy
- MRI parameters shows there's no myometrial invasion, extension beyond corpus, or enlarged lymph nodes
- Have a desire for remaining reproductive function or uterus
- Need to be able to undergo correlative treatment and follow-up
Who cannot join
- Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
- Pregnancy or suspicion of pregnancy
- Have a history of EAH or EC and have disease relapse during Merina insertion
- Under treatment of high-dose progestin therapy more than 3 months in recent 6 months
- Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
- Confirmed diagnosis of malignant tumor in genital system
Show all 10Show fewer
- Acute severe disease such as stroke or heart infarction or a history of thrombosis disease
- Hypersensitivity or contradiction to any component of this product
- Ask for removal of the uterus or other conservative treatment
- Smoker(>15 cigarettes a day)
Trial locations and contacts
1 site in 1 country.
China1 site
Obstetrics and Gynecology Hospital, Fudan University
Shanghai, Shanghai Municipality, 200011
About this study
Official title: Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer
To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate alone in patients with early endometrial cancer.
Read the detailed description
After diagnosed of endometrioid endometrial cancer (EEC) by hysteroscopy, patients will be enrolled. Age, waist circumstances, blood pressure, basic history of infertility, blood pressure, serum lipid level and side effects will be collected. Blood tests, including fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG, sex hormone levels, blood lipids and anti-müllerian hormone(AMH) will be performed before treatment to evacuate their metabolic conditions.
Patients are randomized to 1 of 2 treatment groups. Patients will receive MA (megestrol acetate) 160 mg by mouth daily for at least 3 months on Arm I. Patients will receive MA 160 mg plus LNG-IUS insertion for at least 3 months on Arm II. Then an hysteroscope will be used to evaluate the endometrial condition every 3 months, and the findings will be recorded. For patients with EEC, complete response (CR) is defined as the reversion of endometrial disease to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypic or atypical hyperplasia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the progression of endometrial lesions. Continuous therapies will be needed in PR, NR or PD.
As the reason of the low response rate of LNG-IUS alone in EC patients (nearly 50%), and the potential limitation of LNG-IUS to focal cancer lesion in endometrial cavity, the investigators did not add LNG-IUS alone as a single control group.
After completion of study treatment, 2 months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.
- Conditions
- Endometrial Neoplasm Malignant Stage I
- Being tested
- Megestrol Acetate, Levonorgestrel-releasing Intrauterine System(LNG-IUS)
- Medical subject headings
- Endometrial Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Megestrol AcetateDrug
Also called Megace
At a dosage of 160 mg/day
Levonorgestrel-releasing Intrauterine System(LNG-IUS)Device
Also called Mirena Intrauterine Device, Mirena
levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
| Study group | Role | What they receive |
|---|---|---|
| MA | Active comparator | Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded. Receives: Drug: Megestrol Acetate |
| MA+LNG-IUS | Experimental | Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded. Receives: Drug: Megestrol Acetate; Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pathological response rate
Measured: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
Pathological response time
median time of histologic regression from endometrial atypical hyperplasia to benign endometrium
Measured: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
Secondary outcomes (4)
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Common side effects from these drugs include weight gain, vaginal spotting and descent of sexuality. Severe side effects include thrombus and diseases related. The investigators will record any mental or body symptoms and evaluate the correlation.
Measured: up to 2 years after the treatment for each patient
Rate of relapse
Measured: up to 2 years after the treatment for each patient
Rate of pregnancy
Measured: up to 2 years after the treatment for each patient
Compliance
The investigators designed a questionnaire to evaluate the compliance through treatment as side effects of oral megestrol acetate may be more common than LNG-IUS. Self Efficacy, physical activity and social support will be scored (1 to 5) and compared between different arms.
Measured: up to 2 years after the treatment for each patient
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2017
- Study start4 Jul 2017
- Primary completion18 Jun 2020
- Study completion18 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Endometrial Neoplasm Malignant Stage IStudies of the same condition, open and under way.
- More trials run by Fudan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fudan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Xiaojun Chen, Obstetrics & Gynecology Hospital of Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03241914
- Sponsor's protocol ID
- 2017-30-2
- Status last verified
- Nov 2020
- First submitted
- 12 Jul 2017
- Last updated
- 20 Nov 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Xu Z, Yang B, Guan J, Shan W, Liao J, Shao W, Chen X. Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). J Gynecol Oncol. 2023 Jan;34(1):e32. doi: 10.3802/jgo.2023.34.e32. Epub 2022 Dec 15.
PubMed 36562136
Study at a glance
From the registry record, last updated by the sponsor on 20 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer
- ClinicalTrials.gov ID
- NCT03241914
- Acronym / sponsor ID
- 2017-30-2
- Conditions
- Endometrial Neoplasm Malignant Stage I
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Fudan UniversityUniversity, hospital or other
- Study start
- 4 Jul 2017 (actual)
- Primary completion
- 18 Jun 2020 (actual)
- Study completion
- 18 Jun 2020 (actual)
- First posted
- 8 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will not be inferior to returning the endometrial tissue to a normal state than megestrol acetate alone in patients with early endometrial cancer.
Detailed description
After diagnosed of endometrioid endometrial cancer (EEC) by hysteroscopy, patients will be enrolled. Age, waist circumstances, blood pressure, basic history of infertility, blood pressure, serum lipid level and side effects will be collected. Blood tests, including fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG, sex hormone levels, blood lipids and anti-müllerian hormone(AMH) will be performed before treatment to evacuate their metabolic conditions.
Patients are randomized to 1 of 2 treatment groups. Patients will receive MA (megestrol acetate) 160 mg by mouth daily for at least 3 months on Arm I. Patients will receive MA 160 mg plus LNG-IUS insertion for at least 3 months on Arm II. Then an hysteroscope will be used to evaluate the endometrial condition every 3 months, and the findings will be recorded. For patients with EEC, complete response (CR) is defined as the reversion of endometrial disease to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypic or atypical hyperplasia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the progression of endometrial lesions. Continuous therapies will be needed in PR, NR or PD.
As the reason of the low response rate of LNG-IUS alone in EC patients (nearly 50%), and the potential limitation of LNG-IUS to focal cancer lesion in endometrial cavity, the investigators did not add LNG-IUS alone as a single control group.
After completion of study treatment, 2 months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MA | Active comparator | Drug: Megestrol AcetatePatients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded. |
| MA+LNG-IUS | Experimental | Drug: Megestrol Acetate, Device: Levonorgestrel-releasing Intrauterine System(LNG-IUS)Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Primarily have a confirmed diagnosis of endometrioid endometrial cancer based upon hysteroscopy
- MRI parameters shows there's no myometrial invasion, extension beyond corpus, or enlarged lymph nodes
- Have a desire for remaining reproductive function or uterus
- Need to be able to undergo correlative treatment and follow-up
Key exclusion criteria (10 listed)
- Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
- Pregnancy or suspicion of pregnancy
- Have a history of EAH or EC and have disease relapse during Merina insertion
- Under treatment of high-dose progestin therapy more than 3 months in recent 6 months
- Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Megestrol AcetateAlso: MegaceAt a dosage of 160 mg/day | Drug | MA, MA+LNG-IUS |
| Levonorgestrel-releasing Intrauterine System(LNG-IUS)Also: Mirena Intrauterine Device, Mirenalevonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system. | Device | MA+LNG-IUS |
Primary outcome
Pathological response rate
Time frame: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
Pathological response time
Time frame: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months
median time of histologic regression from endometrial atypical hyperplasia to benign endometrium
4 secondary outcomes
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: up to 2 years after the treatment for each patient
Rate of relapse
Time frame: up to 2 years after the treatment for each patient
Rate of pregnancy
Time frame: up to 2 years after the treatment for each patient
Compliance
Time frame: up to 2 years after the treatment for each patient
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Nov 2020.
- Derived from this study: PubMed 36562136Xu Z, Yang B, Guan J, Shan W, Liao J, Shao W, Chen X. Comparison of the effect of oral megestrol acetate with or without levonorgestrel-intrauterine system on fertility-preserving treatment in patients with early-stage endometrial cancer: a prospective, open-label, randomized controlled phase II trial (ClinicalTrials.gov NCT03241914). J Gynecol Oncol. 2023 Jan;34(1):e32. doi: 10.3802/jgo.2023.34.e32. Epub 2022 Dec 15.
Related trials for Endometrial Neoplasm Malignant Stage I
RecruitingPhase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Active, not recruitingPhase 2
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7
Active, not recruitingPhase 2
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Endometrial Neoplasm Malignant Stage I
Active, not recruitingEarly Phase 1
A Study of a Weight Loss Intervention in People With Endometrial Cancer
Endometrial Cancer
Recruiting
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Megestrol Acetate and Levonorgestrel-releasing Intrauterine System(LNG-IUS) in people with Endometrial Neoplasm Malignant Stage I, run by Fudan University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pathological response rate (time frame: From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03241914, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2020.